MacroGenics, Inc. — Q1 2021 Form 10-Q
Business context and reporting period. Unaudited results cover the three months ended March 31, 2021, compared with Q1 2020. MacroGenics is a clinical-stage biopharmaceutical company that launched its first approved product, MARGENZA, in March 2021. It also develops antibody-based therapies and receives collaboration and government-contract revenue.
Financial performance
| Metric | Q1 2021 | Q1 2020 / comparison |
|---|---|---|
| Total revenue | $16.9 million | $13.7 million; up 23% |
| Collaborative and other revenue | $15.2 million | $13.0 million |
| Product revenue | $0.9 million | None |
| Government-agreement revenue | $0.8 million | $0.7 million |
| Research and development | $53.1 million | $48.9 million; up 9% |
| Selling, general and administrative | $15.0 million | $10.2 million; up $4.8 million |
| Operating loss | $51.3 million | $45.4 million |
| Net loss | $51.3 million | $44.7 million |
| Basic and diluted loss per share | $0.90 | $0.91 |
| Operating cash used | $29.0 million | $44.1 million |
Reported product cost of sales was only $17,000, yielding approximately $0.9 million of product gross profit. The filing says Q1 sales were supplied from product costs expensed as R&D before MARGENZA’s FDA approval; therefore, this early gross-profit figure does not reflect the full ongoing manufacturing cost profile.
Balance sheet, liquidity and cash flow
- At March 31, cash and cash equivalents were $218.5 million and marketable securities were $124.7 million, totaling $343.2 million, versus $272.5 million at December 31, 2020.
- Current assets were $374.7 million and current liabilities $53.0 million. Total assets were $435.4 million; stockholders’ equity was $350.5 million.
- The balance sheet lists no conventional borrowings. Lease liabilities totaled $28.6 million, including current and non-current portions.
- Cash increased $37.4 million during the quarter: $100.7 million from financing, primarily the at-the-market stock offering; $29.0 million used in operations; and $34.3 million used in investing, primarily net purchases of marketable securities.
- The company sold 3.62 million shares through its ATM offering for net proceeds of $98.2 million. Shares outstanding rose from 56.2 million at year-end to 60.0 million at March 31.
Material changes and management commentary
- Revenue rose $3.2 million, principally due to a $10.0 million Incyte development milestone, $3.1 million under the new Incyte commercial-supply agreement, and initial MARGENZA sales. These gains were partly offset by lower Incyte clinical-supply revenue, the absence of a prior-year Zai Lab milestone, and the end of recognition of a former Servier collaboration fee.
- R&D increased $4.2 million, with higher spending on flotetuzumab, MGC018, MGD019 and preclinical programs; lower retifanlimab development and manufacturing activity partially offset the increases. Management expects R&D spending to continue increasing as the pipeline advances.
- SG&A rose primarily because of MARGENZA launch costs; management expects these costs to increase as commercialization continues. The company expects MARGENZA revenue to grow, but provided no quantified sales guidance.
- Management stated that cash, cash equivalents and marketable securities, together with anticipated and potential collaboration payments and product revenue, should fund operations through 2023, assuming programs and collaborations advance as planned. Separately, the financial-statement note says current liquidity is expected to fund operating plans for at least 12 months from the filing date. Additional capital may be needed; availability and terms are uncertain.
Risks, contingencies and unusual items
- COVID-19 had slowed clinical-trial enrollment and could further affect trials, supply chains, collaborators, commercialization and financing. Management expected some near-term impact on new-study initiation and enrollment.
- Clinical outcomes and timing, regulatory approvals, MARGENZA’s market acceptance, competition, manufacturing recovery, collaboration performance and future financing are material uncertainties.
- A securities class action concerning statements about the SOPHIA trial remained pending. The company intends to defend the case, but could not estimate a possible loss and recorded no liability.
- The $10.0 million Incyte milestone was recognized as revenue in Q1 after the company determined it met the recognition threshold. MARGENZA inventory began being capitalized after FDA approval; inventory was $6.2 million at quarter-end.
- Management reported effective disclosure controls. It added controls for product revenue and inventory following the MARGENZA launch. The filing reported no material change to the risk factors in the 2020 Form 10-K.
Most important facts for investors to verify
- Whether MARGENZA sales grow and whether net revenue and margins remain sustainable as pre-approval, previously expensed inventory is used up.
- Clinical-trial progress, enrollment and data timing across the pipeline, and regulatory outcomes, including the Incyte retifanlimab review targeted for July 25, 2021.
- Actual cash burn and whether the stated runway through 2023 remains achievable under the company’s assumptions.
- Future dilution or financing needs, and the timing and amount of collaboration milestones, royalties and supply revenue.
- Developments in the securities litigation and any resulting financial exposure.